AstraZeneca’s Asthma Drug Shows Promise in New Oesophagus Disorder
What Happened
AstraZeneca and Amgen said their asthma drug Tezspire achieved the main goals of a late-stage study in patients with eosinophilic esophagitis, a chronic inflammatory condition that affects the oesophagus and can make swallowing difficult. Patients receiving the drug showed lower inflammation levels and improved swallowing compared with those given a placebo.
Key Takeaways
The successful trial broadens Tezspire’s potential use beyond severe asthma and provides a much-needed positive development for AstraZeneca’s drug pipeline after several recent clinical setbacks.